Summary Coxsackievirus B1 (CVB1), a clinically significant human enterovirus, causes a wide spectrum of diseases ranging from mild illness to severe, life-threatening conditions in susceptible individuals. However, investigations into CVB1 infection pathogenesis, as well as the development and evaluation of antiviral s...
Chang-Jian Fang, Kang Yu, Jia Xue et al.· iScience· 0 citations
This study initiated a multidimensional combination therapy of dexamethasone, heparin and the broad-spectrum viral decoy CoVR-MV at three days after infection and resulted in a potent reduction of high mortality, body weight loss, viral load, lung pathology and cytokine storm.
Ming Zhou, Xuan Liu, Jin-Xin Miao et al.· Molecular Biomedicine· 0 citations
The continued evolution of SARS-CoV-2 has reduced the protective effectiveness of first-generation vaccines and underscores the need for broadly reactive next-generation vaccine candidates. Here, we evaluated STFKB, an alum-adjuvanted bivalent recombinant protein vaccine composed of the monomeric Spike (STFKprototype)...
Zi-Kang Wang, Jia-Hua Gao, Ru Bai et al.· Viruses· 0 citations
It is demonstrated that a rational combination of pharmacological targeting of innate and adaptive immune responses is sufficient to reduce mortality and severe illness caused by beta, delta and EG.1 variants in SARS-CoV-2 infection.
Ming Zhou, Xuan Liu, Haiqing Xiao et al.· Molecular Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
